Supervisory Board

Member of the BRAIN Biotech AG Supervisory Board since March 7, 2019; Chairman since March 8, 2023; appointed until the end of AGM in FY 2026/27

• Member of the audit committee, personnel committee (chair) and nomination committee
• Key areas of expertise: Entrepreneurship; New business areas; Corporate finance/capital markets; Internationality; M&A; Controlling & Risk management; Knowledge in the field of auditing and accounting (pursuant to §§ 107 (4), 100 (5) AktG); Sustainability

Born in 1961

Nationality: German

Education

• 1980 - 1985 Study of Business Administration at the University of Cologne, Germany, holding a degree in Business Administration (Diplom-Kaufmann)
• 1986 - 1989 Assistant at the Institute of Business Adminsitration V of the University of Siegen, Germany, doctorated in economics in 1989

Professional career

• 1989 – 2000: Mannesmann AG, Duesseldorf, Germany
• 1989 - 1991 Controlling Department (including Investor relations)
• 1991 - 1999 Various management positions at Mannesmann Ag and Mannesmann Demag AG, inter alia responsible for international projects including mergers & aquisitions
• 1999 - 2000 Central divisional Head of Controlling and Accounting at Mannesmann AG and later 2000 at Mannesmann Atecs AG
• Member of the Supervisory Board of Mannesmann Austria AG

• 2000 – 2006: Infineon Technologies AG, Munich, Germany
• Member Divisional Management Board and CFO Memory Products Group
• Member of the Supervisory Board or Board of Directors of related companies in Germany, Taiwan, China, USA and Portugal
• 2006 – 2009: Qimonda AG, (former Infineon Technologies AG Memory Products Division), Munich, Germany
• Member of the Management Board & Chief Financial Officer (CFO) and employee relations director (Arbeitsdirektor), Implementation of company’s IPO at the New York Stock Exchange in 2006
• Member of the Supervisory Board or Board of Directors of related companies in Germany (Chairman), Portugal (Chairman), Taiwan, China and USA

• 2009 – 2013: PHOENIX Pharmahandel GmbH & Co KG, Mannheim, Germany
• Member of the Management Board & Chief Financial Officer (CFO)
• Member of the Supervisory Board or Board of Directors of related companies in Germany, UK, France, Italy, Netherlands, Switzerland, Austria, Finland and other countries in Eastern Europe

• 2014 – 2020: SGL Carbon, SE, Wiesbaden, Germany
• Member of the Management Board & Chief Financial Officer (CFO)
• Spokesman of the Management Board (9/2019 – 5/2020)
• Member of the Supervisory Board or Board of Directors of related companies in Germany, Portugal (Chairman), Poland (Chairman), USA (Chairman) and China

• Since 2013 Partner in Neofon GmbH, Starnberg, Germany

Further memberships of statutory Supervisory Boards in Germany:

Deputy Chairman of the Supervisory Board of Team Neusta AG, Bremen, Germany

Further memberships in comparable German and foreign Supervisory Boards:

None

Independent within the meaning of Section C.6, C.7 and C.9 of the German Corporate Governance Code:

Yes

Last update: September 2024

Member of the BRAIN Biotech AG Supervisory Board since March 9, 2017; Vice Chairwoman since March, 5, 2020; appointed until the end of AGM in FY 2024/25

• Member of the nomination committee (chair)
• Key areas of expertise: Entrepreneurship; New business areas; Sector; Internationality

Born in 1972

Nationality: German

Education

• Foundation course in chemistry and biology
• 1998 degree in biochemistry from Johann Wolfgang Goethe University, Frankfurt/Main, Germany
• 2003 academic degree of Disputation

Professional Career

• 2001 – today: Co-Founder humatrix AG, Frankfurt/Main - today in Pfungstadt, Germany
  Chief Technology Officer (CTO)
  Since 2012: Chief Executive Officer (CEO)

• 2014 – today: House of Pharma & Healthcare Association, Frankfurt/Main, Germany - Management Board Member

• 2007 – today: Initiative gesundheitswirtschaft-rhein-main Association, Frankfurt/Main, Germany - Deputy Chief Executive Officer (CEO)

• 2006 – 2016: European Journal of Clinical Pharmacology (EJCP), Germany - Scientific consultant

• 2023 – today: Charlotte Fresenius University of Applied Sciences in Wiesbaden, Germany - lecturer 

Further memberships of statutory Supervisory Boards in Germany:

None

Further memberships in comparable German and foreign Supervisory Boards:

Member of the Supervisory Board of the Frankfurter Innovationszentrum Biotechnologie GmbH (FiZ), Frankfurt/Main, Germany

Independent within the meaning of Section C.6, C.7 and C.9 of the German Corporate Governance Code:

Yes

Last update: September 2024

Member of the Supervisory Board of BRAIN Biotech AG since October 14, 2020; appointed until the end of AGM in FY 2024/25

• Member of the personnel committee
• Key areas of expertise: Entrepreneurship; New business areas; Sector; Internationality; M&A

Born in 1965

Nationality: British

Education

• Study Food Science and Technology at Reading University, UK; Graduated in 1987 (BSc, First class, Honors)

Professional Carreer

• 1987 - 1991: Kraft General Foods: European Product Development Manager (based in Germany)

• 1991 - 2003: Danisco A/S (today Dupont): Sales & Marketing Manager UK; Business Unit Manager Textural Ingredients (based in Denmark); Managing Director and Sales Director UK ; Divisional Chief Executive Officer (CEO) Flavours

• 2003 - 2014: Associated British Foods (ABF) plc, UK: Divisonal Chief Executive Officer (CEO) - ABF Ingredients

• 2014 - today: SJ Catling Ltd., UK: Managing Director focus on the use of equity capital for start-ups, mergers and acquisitions, consulting to the food, nutrition and bio ingredients industries

Further memberships in statutory supervisory boards in Germany:

None

Other memberships in comparable domestic and foreign supervisory bodies:

• Chairman of the Board of the Cambridgeshire Community Foundation in the UK (since October 2021)
• Chairman of the Board of Condimentum UK Ltd, (since Sept 2023)
• Chairman of the Board of Arborea UK/Portugal (since Dec 2023)
• Non Executive Director of Oceanium Ltd UK (since Dec 2023)
• Non Executive Director of JPL Flavour Technologies Ltd  UK (since March 2024)

Independent within the meaning of Sections C.6, C.7 and C.9 of the German Corporate Governance Code:

Yes

Last update: September 2024

Member of  the BRAIN Biotech AG Supervisory Board since March 8, 2023; appointed until the end of AGM in FY 2026/27

• Member of the audit committee
• Key areas of expertise: Corporate finance/capital markets; Internationality; M&A; Controlling & Risk management

Born in 1970

Nationality: German

Education

• Law at universities Munich and Bayreuth, Germany
• Doctorate at University of Regensburg, germany; MBA at University of Rochester, USA and University of Leuven, Belgium

Professional Career

• 1999 – 2000: Bavarian Tax Administration: Senior civil servant

• 2001 – 2003: Ebner Stolz & Partner, Munich, Germany: Lawyer and tax consultant - Focus: tax advice for corporate restructuring and estate planning

• 2003 – 2017: Allianz SE, Munich, Germany: Head of Corporate Taxation - Responsible for  tax affairs of 140 operating legal entities  and German based Sub-groups

• 2017 – 2021: WTS, Munich, Germany: Partner; Establishment of new tax advisory service line for clients from the insurance and financial services industry; Standardization and industrialization of tax business partnering service offering across industry lines  

• Since 2022: MP BeteiligungsGmbH, Stuttgart, Germany: Managing Director - Management of company assets, Family Office Services for owner family

• Since 2022: BSN GmbH, Kaiserslautern, Germany: Managing Director

Further memberships of statutory Supervisory Boards in Germany:

None

Further memberships in comparable German and foreign Supervisory Boards:

None

Independent within the meaning of Section C.6, C.7 and C.9 of the German Corporate Governance Code:

No

Last update: September 2024

Member of the BRAIN Biotech AG Supervisory Board since October 14, 2020; appointed until the end of AGM in FY 2024/25

• Member of the personnel committee
• Key areas of expertise: New business areas; Sector; Internationality; M&A; Sustainability

Born in 1954

Nationality: German

Education

• 1973 - 1979: Technical University Berlin, Germany: Food & Biotechnology
• 1979: Biochemical Engineer 
• 1983: PhD University Dortmund, Germany - Dept. of Technical Chemistry: Prof. Dr. Ulfert Onken

Academic experience

• 1987 - 2005: Teaching Assignment at the University of Hannover, Germany: Biochemical Engineering
• 1995: Awarded with title Professor

Professional career

• 1984 - 2000: Degussa / Evonik, Hanau (Germany)
• 1984 - 2000: Biochemical and Environmental Process Technology - Director: Biochemical and Environmental Process Technology within the Process Technology Function of the company 
• 1987: Leader Biochemical Engineering Group, later expanded to Environmental Process Technology
• 1995: Member of Global Leadership Team; built new organization for Biochemical and Environmental Engineering; new waste gas purification process in industrial scale; scale up of process for Biolys in >500.000 L reactor, including downstream process in Slowakia; transferred to Blair Nebraska (US)

• 2001 – 2019: Dow, Dow AgroSciences and DowDuPont (Germany, UK, USA)
• 2001 - 2002: Corporate R&D Leader Dow Industrial Biotechnology Europe, Frankfurt (Germany)
  New Business Platform Industrial Biotechnology and Corp. R&D Industrial Biotechnology /San Diego and Midland/US; Custom & Fine Chemicals: ChiroTech (biocatalysis) in Cambridge, UK and BCMS in Smithfield/RI: CMO for biopharmaceuticals; Managed and re-directed existing external research projects
• 2003 - 2005: Global Director Biopharma R&D/ DowPharma, San Diego (USA)
  Developed a new Biopharma business strategy; Designed, established and lead Biopharma R&D organization; Consolidated existing R&D sites; built customer orientated team
• 2005 - 2011: Global Director Bioprocess R&D, Dow AgroSciences, Indianapolis (USA)
  Built new integrated function in R&D including new capabilities like HT screening, metabolic engineering, fermentation, protein expression, oilseed processing and automation; improved significantly the value generation in the areas of insecticides, animal health and alternative feedstock
• 2011 - 2019: Chief Technology Officer (CTO) Europe, Middle East, Africa & India; Dow/DowDuPont, Horgen (Switzerland)
  Member of EMEAI Executive Leadership Team; designed and implemented R&D site strategy for entire portfolio of Dow in EMEA; developed and implemented new Dow Middle East Innovation Center at KAUST (Saudi Arabia); collaborated with government, universities and key customers; technical leadership for new business development; developed customer innovation toolbox for improved customer interaction with key accounts; developed and implemented geographic R&D strategy for merger and split of Dow & DuPont; member of the Supervisory Board Dow Central Germany

•  June 2019 - today: Advisor and consultant for scientific organizations and Member of Supervisory Boards
• Since 1985 actively involved in scientific committees and organizations such as Dechema, OECD, GVC and VCI
• Member of both bioeconomy councils of the German government
• Member of the Board of Trustees of the Fraunhofer Institute for Systems and Innovation Research ISI, Karlsruhe and of the Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB, Stuttgart (Germany)
• Expert and consultant to German and Swiss universities
• Since June 2019 independent consultant, in particular for SMEs and scientific organizations

Further memberships of statutory Supervisory Boards in Germany:

Member of the Supervisory Board oft he ProBioGen AG, Berlin

Further memberships in comparable German and foreign Supervisory Boards:

None

Independent within the meaning of Section C.6, C.7 and C.9 of the German Corporate Governance Code:

Yes

Last update: September 2024

Member of the BRAIN Biotech AG Supervisory Board since March 8, 2023; appointed until the end of AGM in FY 2026/27

• Member of the audit committee (chair)
• Key areas of expertise: New business areas; Corporate finance/capital markets; Sector; Internationality; M&A; Controlling & Risk management; Expertise in the auditing area (pursuant to Sections 107 (4), 100 (5) AktG); Specialist knowledge in the area of financial auditing (pursuant to Sections 107 (4), 100 (5) AktG)

Born in 1964

Nationality: German

Education

• 1985 – 1989 Study Art and Italian at Freie University of Berlin, Germany
• 2004: Gratuated with a degree in business administration at Verwaltungs- und Wirtschaftsakademie Berlin, Germany
• 2008: CINA Certificate in International Accounting (IFRS, US GAAP) at the Akademie für Internationale Rechnungslegung (Academy for International Accounting), Cologne, Germany

Professional career

• 2000 – 2006: SAP SI AG / SPM Technologies GmbH
  Vice President Finance; played a key role in growing the company from 20 to over 400 employees and facilitated the successful merger with SAP 

• 2006 – 2009: ProBioGen AG, Berlin, Germany
  Director Finance & Administration; oversaw a significant restructuring of the company, successfully commercializing its technology; led the exit of investors through a merger with Minapharm Pharmaceuticals

• 2009 – 2011: OD-OS GmbH (Medical Technology Company), Teltow, Germany and San Francisco, USA
  Vice President Finance and Executive with General Power of Attorney

• 2011 – 2016: Centogene N.V., Rostock, Germany and Boston, USA
  Chief Financial Officer (CFO)
  Led the development of the company’s financial architecture and international expansion strategy; Supported significant company growth, resulting in a tenfold revenue increase within five years

• Since 2016: Evolve Partners – Biofin Consulting GmbH (formerly nsight Consulting GmbH), Berlin, Germany
  Managing Director; Provides a managed finance suite and consulting services focused on growing, international technology, and biotechnology companies Held interim executive roles, including:
  Interim CFO at the publicly listed Curasan AG and Interim Chief Strategy Officer (CSO) at genetics startup Arcensus GmbH

Further memberships of statutory Supervisory Boards in Germany:

None

Further memberships in comparable German and foreign Supervisory Boards:

None

Independent within the meaning of Section C.6, C.7 and C.9 of the German Corporate Governance Code:

Yes

Last update: September 2024